These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17453371)

  • 1. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
    Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
    Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
    Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G
    Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
    Wong ZW; Ang PC; Chowbay B; Wong NS; See HT; Khoo KS
    Breast; 2008 Oct; 17(5):517-22. PubMed ID: 18502128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
    Jacquin JP; Chargari C; Thorin J; Mille D; Mélis A; Orfeuvre H; Clavreul G; Chaigneau L; Nourissat A; Dumanoir C; Savary J; Merrouche Y; Magné N
    Am J Clin Oncol; 2012 Feb; 35(1):18-21. PubMed ID: 21278560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
    Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
    Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
    Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
    Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
    Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
    J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
    Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
    Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
    Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
    Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
    Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
    Del Barco S; Colomer R; Calvo L; Tusquets I; Adrover E; Sánchez P; Rifà J; De la Haba J; Virizuela JA
    Breast Cancer Res Treat; 2009 Jul; 116(2):351-8. PubMed ID: 18941891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    Tas F; Guney N; Derin D; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.
    Lombardi G; Zustovich F; Farinati F; Cillo U; Vitale A; Zanus G; Donach M; Farina M; Zovato S; Pastorelli D
    Cancer; 2011 Jan; 117(1):125-33. PubMed ID: 21058409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
    El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
    J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
    Poh SB; Bai LY; Chen PM
    Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Papakostas P; Dafni U; Makatsoris T; Karina M; Kalogera-Fountzila A; Maniadakis N; Aravantinos G; Syrigos K; Bamias A; Christodoulou C; Economopoulos T; Kalofonos H; Nikolaou A; Angouridakis N; Stathopoulos G; Bafaloukos D; Pavlidis N; Daniilidis J
    Ann Oncol; 2006 Oct; 17(10):1560-7. PubMed ID: 16790517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
    Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
    J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.